Načítá se...

The safety and efficacy of osimertinib for the treatment of EGFR T790M mutation positive non-small-cell lung cancer

First- and second-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are the evidence-based first-line treatment for metastatic non-small-cell lung cancers (NSCLCs) that harbor sensitizing EGFR mutations (i.e., exon 19 deletions or L858R). However, acquired resistan...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Expert Rev Anticancer Ther
Hlavní autoři: Gao, Xin, Le, Xiuning, Costa, Daniel B.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2016
Témata:
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4940973/
https://ncbi.nlm.nih.gov/pubmed/26943236
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1586/14737140.2016.1162103
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!